The potential deletion of the drug-binding region may lead to a direct loss of drug-binding function of CRBN; however, it is unclear if the relative amount of full-length CRBN present in the tumor cells may be sufficient to confer drug sensitivity, especially for a more potent compound. This evidence concerns the gene CRBN and neoplasm.